Behind the markets

Daily Trades

December 2024 Issue: Esperion (SYM: ESPR) & Updates (KURA, IOVA)

This climate of fear is our friend. It has created opportunities in the biotech sector which will look downright silly in three to five years.
Learn More

June 2024 Issue: Esperion Therapeutics (SYM: ESPR)

Now the company can aggressively market these drugs to as many as 70 million people.
Learn More

May 2024 Issue: Biogen (SYM: BIIB) & Updates (IOVA, ESPR)

My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
Learn More

December 2023 Issue: Altimmune, Inc. (SYM: ALT)

For our December issue, I’m adding a stock to our weight-loss trade: Altimmune (SYM: ALT) here at $3.75.
Learn More

November 2023 Issue: Esperion Therapeutics (SYM: ESPR)

When I see that the stock is selling for just $1.19 per share - and billionaire investors Steve Cohen and Jim Simons own 3.5 million shares, count me interested.
Learn More

Our #1 Micro-Cap Biotech Stock for April – Esperion Therapeutics (ESPR)

Pharmaceutical company Esperion Therapeutics (SYM: ESPR) develops and commercializes medicines for the treatment of patients with elevated lowdensity lipoprotein cholesterol, or LDL – the “bad” cholesterol, which makes up a good deal of your body’s total cholesterol.
Learn More

March 2023 Issue: Schrodinger (SYM: SDGR)

A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it. 
Learn More

March 2022 Issue – Esperion Therapeutics

At around $5 per share, I think Esperion Therapeutics (SYM: ESPR), will go down as one of the best biotech buys you’ve ever made.
Learn More

January 2022 Issue: FDA Approvable Letter Calendar & Updates

Learn More

September 2020 Issue: Combating Cardiovascular Disease

Learn More

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Get Deal

Categories

Behind the Markets

2.2K subscribers

Independent Research for Independent Investors

Behind the Markets
Happy Friday—and happy Bring Your Child to Work Day! Teddy is here with me today, and it’s one of my favorite traditions. He gets to see what I do, meet the team, and, of course, raid the donut stash. But between the sugar rush and showing him the ropes, I wanted to touch on something important: the market's recent volatility. Right now, April is shaping up to be one of the most volatile months in decades. We’re seeing intraday swings not seen since COVID—and before that, only in 2008 and 1987. That kind of historic volatility isn't random. We’ve got earnings reports that look good on paper, but CEOs are warning about tariff impacts and rising input costs. It’s created a strange split-screen effect: strong fundamentals on one side, but geopolitical and inflation fears on the other. Then there’s China. One minute the Trump administration is imposing tariffs, the next they’re walking it back. Treasury Secretary Scott Bessent even called it a “trade embargo” during a JP Morgan conference, which is serious language. It reminds me of the embargoes that led to World War I, World War II—and yes, even Pearl Harbor. When trade stops, tempers flare. So where does that leave us? In the middle of a market being driven more by politics and external shocks than pure economic data. That’s why anyone who tells you they know exactly where the market is going is, frankly, full of it. All we can do is stay grounded, stay informed, and not let the bull-bear tug-of-war pull us off course. ✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼 https://www.youtube.com/channel/UCczJ4YRRQLl6KrH06iapaRw?sub_confirmation=1 ✅ SIGN UP FOR DYLAN'S DIARY HERE 👇🏼👇🏼 https://go.behindthemarkets.com/dylans-diary-sign-up/ ✅ VISIT OUR WEBSITE 👇🏼👇🏼 https://behindthemarkets.com/
YouTube Video VVVjeko0WVJSUUxsNktySDA2aWFwYVJ3Lm9sTHNBZThMQmFJ

Dylan Jovine | Bull? Bear? Nobody Knows. China Tariffs Spark Volatility and Wall Street Confusion

Hey everyone — it’s Dylan Jovine here with another episode of Behind The Markets. Happy Thursday to you all. Today’s episode dives headfirst into a topic that's been lighting up my inbox lately: who really owns America’s debt? I’ve probably been asked this 50 times over the past two weeks, so I figured it’s time to break it down for you. And honestly, the numbers might surprise you. I also wanted to unpack what’s happening behind the scenes in the bond markets because it’s exposing some very real weaknesses in the U.S. financial situation. We’re witnessing a critical moment where our debt is starting to choke our flexibility as a country — not in theory, but in practice. This isn’t something off in the future. It’s happening right now, with major foreign creditors adjusting their strategies and Treasury yields making the biggest moves we've seen in 25 years. Plus, I’ll touch on how this debt dilemma is influencing policy decisions, like Trump’s sudden tariff flip-flop earlier this month. And as always, I’ll tie it back to real life — whether it’s how we manage our own finances when times get tough, or how the market’s recent volatility is giving us a very clear message. Thanks for being here with me, and as always, I appreciate you tuning in. Make sure to subscribe if you haven’t yet — I’ll be back tomorrow with more. ✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼 https://www.youtube.com/channel/UCczJ4YRRQLl6KrH06iapaRw?sub_confirmation=1 ✅ SIGN UP FOR DYLAN'S DIARY HERE 👇🏼👇🏼 https://go.behindthemarkets.com/dylans-diary-sign-up/ ✅ VISIT OUR WEBSITE 👇🏼👇🏼 https://behindthemarkets.com/
YouTube Video VVVjeko0WVJSUUxsNktySDA2aWFwYVJ3LktoVzFKNHJVOHpN

Dylan Jovine | US Debt Crisis 2025: Why Creditors Are Dumping Treasuries

Good morning and happy Wednesday! In today’s episode of Behind the Markets, I’m diving into a powerful story that caught my attention in the Wall Street Journal—April 2025 is shaping up to be the worst April for the markets since the Great Depression. That’s right—we just lived through a historic downturn. But in the middle of this chaos, one asset has been quietly rising: gold. A lot of you have been asking me about gold lately, and I totally get why. While the market’s been tanking, gold just hit an all-time high—$3,457 an ounce. It’s incredible. So today, I’m breaking down why I’m still bullish on gold and what’s really driving its price higher. We’ll talk about the impact of U.S. fiscal spending, currency debasement, and why central banks around the world are loading up on gold. I also dig into something called the “Sell America” trade—this idea that foreign investors are pulling out of U.S. stocks, bonds, and dollars all at once. That’s only happened six times in American history, and it’s a big deal. Add in trade tensions, tariff policies, and global de-dollarization, and gold starts to look like the ultimate safe haven. If you're wondering what all this means for you and your portfolio, tune in—I lay it all out in plain English, with a little humor and a lot of history. Thanks for being part of this journey with me. Let’s get through these markets together. ✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼 https://www.youtube.com/channel/UCczJ4YRRQLl6KrH06iapaRw?sub_confirmation=1 ✅ SIGN UP FOR DYLAN'S DIARY HERE 👇🏼👇🏼 https://go.behindthemarkets.com/dylans-diary-sign-up/ ✅ VISIT OUR WEBSITE 👇🏼👇🏼 https://behindthemarkets.com/
YouTube Video VVVjeko0WVJSUUxsNktySDA2aWFwYVJ3Lm56endhcThzekpn

Dylan Jovine | Why Gold is Soaring While Markets Crash | Worst April Since the Great Depression

Load More... Subscribe

Recent posts

Wall Street’s Favorite Stocks for Summer 2025 – 4/26

Earn 2.77% Yield as Gold Rallies to Historic Highs

Forget AI Stocks – This Is Where the Real Profit’s Hiding – 4/25

Market volatility update

Tags

Connect with Us

Icon-facebook Icon-btmshare_tw

December 2024 Issue: Esperion (SYM: ESPR) & Updates (KURA, IOVA)

This climate of fear is our friend. It has created opportunities in the biotech sector which will look downright silly in three to five years.
Learn More

June 2024 Issue: Esperion Therapeutics (SYM: ESPR)

Now the company can aggressively market these drugs to as many as 70 million people.
Learn More

May 2024 Issue: Biogen (SYM: BIIB) & Updates (IOVA, ESPR)

My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
Learn More

December 2023 Issue: Altimmune, Inc. (SYM: ALT)

For our December issue, I’m adding a stock to our weight-loss trade: Altimmune (SYM: ALT) here at $3.75.
Learn More

November 2023 Issue: Esperion Therapeutics (SYM: ESPR)

When I see that the stock is selling for just $1.19 per share - and billionaire investors Steve Cohen and Jim Simons own 3.5 million shares, count me interested.
Learn More

Our #1 Micro-Cap Biotech Stock for April – Esperion Therapeutics (ESPR)

Pharmaceutical company Esperion Therapeutics (SYM: ESPR) develops and commercializes medicines for the treatment of patients with elevated lowdensity lipoprotein cholesterol, or LDL – the “bad” cholesterol, which makes up a good deal of your body’s total cholesterol.
Learn More

March 2023 Issue: Schrodinger (SYM: SDGR)

A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it. 
Learn More

March 2022 Issue – Esperion Therapeutics

At around $5 per share, I think Esperion Therapeutics (SYM: ESPR), will go down as one of the best biotech buys you’ve ever made.
Learn More

January 2022 Issue: FDA Approvable Letter Calendar & Updates

Learn More

September 2020 Issue: Combating Cardiovascular Disease

Learn More

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
Behind the markets

Company

Explore

CUSTOMER SERVICE

  • We’re here to help.
    Contact Us:
    Mon – Fri | 10 AM – 7 PM EST
  • 1-800-851-1965

© 2025 Behind the Markets, LLC. All rights reserved.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.